ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

Phase 2 Terminated 120 enrolled AstraZeneca ISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALI · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.

Timeline

Start: 2009-06
Primary completion: 2011-06
Completion: 2011-06

Publications

Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). Gynecol Oncol. 2013 Jul;130(1):31-7. doi: 10.1016/j.ygyno.2012.12.004. Epub 2012 Dec 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zibotentan	Small molecule	10 mg	Oral
Background	Carboplatin	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Indications

No indication recorded.